FDA Approves Radioembolization Therapy for Unresectable Hepatocellular Carcinoma
The use of SIR-Spheres achieved a 98.5 percent overall response rate in the treatment of hepatocellular carcinoma in a recent prospective multicenter trial.
Interventional radiologists have a new modality for treating hepatocellular carcinoma (HCC) with the Food and Drug Administration (FDA) issuing an expanded approval for SIR-Spheres Y-90 resin microspheres in the management of unresectable HCC.
Previously approved for the treatment of metastatic colorectal cancer, the SIR-Spheres radioembolization therapy was recently evaluated for the treatment of HCC in the prospective multicenter DOORwaY90 study.
In a prospective multicenter study of SIR-Spheres, researchers found that the median duration of response for patients with hepatocellular carcinoma (HCC) exceeded 300 days. The FDA recently granted an expanded approval of SIR-Spheres for treating unresectable HCC. (Image courtesy of Sirtex Medical.)
Employing personalized dosimetry for the direct delivery of optimal radiation dosing to HCC tumors, researchers found that SIR-Spheres (Sirtex Medical) achieved a 98.5 percent overall response rate, and that the median duration of response exceeded 300 days.
“This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results. This will give multidisciplinary care teams the confidence to recommend SIR-Spheres for HCC treatment,” noted Armeen Mahvash, M.D., a professor in the Department of Interventional Radiology at the University of Texas MD Anderson Cancer Center in Houston, and a co-principal investigator of the DOORwaY90 study.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 1st 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
August 1st 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 1st 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.
